21:22 , Jan 18, 2019 |  BioCentury  |  Politics, Policy & Law

Pharma falling off budget cliff

Three strong arms are lining up in Washington to take turns whacking the biopharma piñata. Divisions within the industry, a lack of new ideas, and resistance to change are making a bad situation worse for...
01:03 , Jan 12, 2019 |  BioCentury  |  Finance

Warning: cash needed

A near decade-long run of cheap money appears to be coming to a close, and most of the biotech sector isn’t well positioned for the new reality. BioCentury’s analysis shows that two-thirds of biotech companies...
01:34 , Dec 15, 2018 |  BioCentury  |  Regulation

FDA to facilitate access to unapproved drugs

FDA plans to launch a new program in 2019 that will help patients gain access to unapproved therapies. The agency will field telephone requests from physicians and patients, streamline the application process, and act as...
21:26 , Nov 20, 2018 |  BC Extra  |  Politics & Policy

Sanders, Khanna propose compulsory licensing to reduce U.S. drug prices

Sen. Bernie Sanders (I-Vt.) announced Tuesday plans to introduce legislation that would impose compulsory licenses on drugs if their prices exceed a reference price derived from an international price index. Rep. Ro Khanna (D-Calif.) said...
20:11 , Sep 13, 2018 |  BC Extra  |  Preclinical News

Paper-based method for POC metabolite diagnosis

A metabolite detection method described in a Science paper published Thursday could provide clinicians with a paper-based point-of-care diagnostic that could potentially measure 42 metabolites implicated in a range of diseases. The method could improve...
20:57 , Aug 24, 2018 |  BC Extra  |  Politics & Policy

Senate approves $2B raise for NIH in FY19

The Senate on Thursday approved a $2 billion increase for NIH to $39.1 billion for FY19 despite the Trump administration's earlier recommendation of steep cuts. A statement from Sen. Roy Blunt (R-Mo.), chair of the...
18:38 , Aug 10, 2018 |  BC Week In Review  |  Clinical News

Second Vertex drug caught in CF standoff

NICE's suspension of its review of Symkevi tezacaftor/ivacaftor on Aug. 9 marks the latest delay of access in England and Wales to cystic fibrosis drugs from Vertex Pharmaceuticals Inc. (NASDAQ:VRTX). NICE suspended its review after...
21:23 , Aug 9, 2018 |  BC Extra  |  Company News

Second Vertex drug caught in CF standoff

NICE's suspension of its review of Symkevi tezacaftor/ivacaftor on Thursday marks the latest delay of access in England and Wales to cystic fibrosis drugs from Vertex Pharmaceuticals Inc. (NASDAQ:VRTX). NICE suspended its review after the...
23:21 , Jul 13, 2018 |  BioCentury  |  Finance

Pause for politics

The near record-setting pace of 1H18 capital markets activity isn’t likely to be replicated this half, but that won’t be because of changes to sector fundamentals. Instead, it’s likely the consequence of macroeconomic and geopolitical...
21:40 , Jul 10, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Sarcoma Cell culture and mouse studies suggest combining Mekinist trametinib with IGF1R inhibitors could help treat PAX3-PAX7 fusion-negative rhabdomyosarcoma. Screening of a panel of 1,912 approved or tool compound small molecule inhibitors in a...